Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2005

View Archived Issues

Rylomine induces analgesic effects in patients with postsurgical orthopedic pain

Celldex Therapeutics acquires Lorantis and assets of Alteris Therapeutics

OGX-011 begins new phase II study in prostate cancer

GPI-0100 adjuvant licensed by Hawaii Biotech

Osiris to begin phase II study of Prochymal for severe GVHD

Arrowhead Research accelerates investment in Insert Therapeutics

Trexima NDA accepted for review

IND filing for MEDI-545 for lupus

RTA-401 cleared for clinical testing

KP-1461 begins phase Ib study for HIV

Talabostat begins phase III for metastatic NSCLC

CHIR-12.12 enters phase I study for multiple myeloma

Inspire completes studies prior to end-of-phase II meeting

Mack and Transport enter agreement for cold sores device/drug product

Aerie closes Series A financing

Phase III program under way for Memryte implant

Benefits of rHuPH20 for cerebral brain ischemia and enhanced pharmacokinetics

M-475271 antitumor effects via inhibition of angiogenesis

Targeting CIDS for CNS injury: a new avenue for therapeutic investigation

New PDE inhibitors disclosed by Altana

Janssen patent claims new opioid receptor agonists for pain

Novel anti-HIV agents reported in recent patent literature

LY-456236 produces anticonvulsant effects in preclinical testing

New data on the metabolic effects of orexin A

Oral insulin prevents postprandial glucose excursions in patients with type 1 diabetes

Pioglitazone improves cardiovascular outcome in patients with type 2 diabetes

Update on the antibacterial efficacy of tigecycline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...